Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quisinostat in Previously Treated Cutaneous T-cell Lymphoma
NCT01486277Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of quisinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Cutaneous Response Rate based on modified Severity Weighted Assessment Tool (mSWAT) criteria. Started Nov 2011; status: completed.
02
Drugs
quisinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01486277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486277.